HIMS Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

617.48M

+28.34%

0.054

-50.53%

658.67M

+12.4%

0.152

-23.85%

660.21M

+21.18%

0.176

+3.44%

Estimates Revision

The market is revising Upward the revenue expectations for Hims & Hers Health, Inc. (HIMS) for FY2025, with the revenue forecasts being adjusted by 0.28% over the past three months. During the same period, the stock price has changed by -41.26%.

Revenue Estimates for FY2025

Revise Upward

+0.28%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-18.7%

In Past 3 Month

Stock Price

Go Down

-41.26%

In Past 3 Month

11 Analyst Rating

Wall Street analysts forecast HIMS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HIMS is 46.25 USD with a low forecast of 30.00 USD and a high forecast of 85.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

6 Hold

3 Sell

Hold

Current: 0.000

Low

30.00

Averages

46.25

High

85.00

Current: 0.000

Low

30.00

Averages

46.25

High

85.00

BofA

Underperform

downgrade

$32 -> $29

2026-01-08

New

Reason

BofA

Price Target

$32 -> $29

2026-01-08

New

downgrade

Underperform

Reason

BofA lowered the firm's price target on Hims & Hers to $29 from $32 and keeps an Underperform rating on the shares. The firm says 2026 consensus estimates for Hims' sales and EBITDA margins are too high. 2026 is a "big investment year" for Hims & Hers and current Street expectations for EBITDA margin expansion "seem overly optimistic," the analyst tells investors in a research note. BofA sees downside risk to 2026 consensus revenue and EBITDA margins and expects negative earnings revisions to take place over the next few months.

Citi

Sell

maintain

$30

2026-01-05

New

Reason

Citi

Price Target

$30

2026-01-05

New

maintain

Sell

Reason

Citi believes Novo Nordisk's (NVO) announcement this morning that its Wegovy weight loss pill is now broadly available throughout the U.S. will pressure Hims & Hers (HIMS). Hims was again left off Novo's partners list, which includes CVS Health (CVS) and Costco (COST), LifeMD (LFMD) and GoodRx (GDRX), which likely reflects disagreements between Novo and Hims around Him's compounded semaglutide strategy, the analyst tells investors in a research note. Citi thinks Novo's pill launch will put pressure on Hims & Hers' GLP-1 business in 2026. The firm keeps a Sell rating on the shares with a $30 price target. The stock in premarket trading is up 44c to $33.85.

Barclays

NULL -> Overweight

initiated

$48

2025-12-08

Reason

Barclays

Price Target

$48

2025-12-08

initiated

NULL -> Overweight

Reason

Barclays initiated coverage of Hims & Hers with an Overweight rating and $48 price target.

Barclays

Overweight

initiated

$48

2025-12-08

Reason

Barclays

Price Target

$48

2025-12-08

initiated

Overweight

Reason

Barclays initiated coverage of Hims & Hers with an Overweight rating and $48 price target. With the concerns around the sustainability of the company's compounding strategy now better understood, the firm believes the expectations around the shares have become more reasonable, the analyst tells investors in a research note. The firm added that, looking forward to FY26, it believes the recent addition of other growth drivers help create a more favorable setup for durable growth.

Seaport Research

Buy

downgrade

$66 -> $59

2025-11-04

Reason

Seaport Research

Price Target

$66 -> $59

2025-11-04

downgrade

Buy

Reason

Seaport Research lowered the firm's price target on Hims & Hers to $59 from $66 and keeps a Buy rating on the shares. Quarterly results showed solid growth trends despite near term headwinds, the analyst tells investors.

BofA

Underperform

maintain

$28 -> $32

2025-11-04

Reason

BofA

Price Target

$28 -> $32

2025-11-04

maintain

Underperform

Reason

BofA raised the firm's price target on Hims & Hers to $32 from $28 and keeps an Underperform rating on the shares after the company reported a "mixed" quarter, with revenue and EBITDA exceeding Street and BofA estimates and total subscribers falling below expectations. The firm sees downside risk to 2026 consensus revenue estimates and lowered its own 2026 EBITDA estimates, but rolls its valuation framework from 2025 to 2026, yielding its increased price target.

Valuation Metrics

The current forward P/E ratio for Hims & Hers Health Inc (HIMS.N) is 56.69, compared to its 5-year average forward P/E of 1.70. For a more detailed relative valuation and DCF analysis to assess Hims & Hers Health Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

1.70

Current PE

56.69

Overvalued PE

56.07

Undervalued PE

-52.66

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

4.99

Current EV/EBITDA

23.70

Overvalued EV/EBITDA

45.30

Undervalued EV/EBITDA

-35.31

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

3.55

Current PS

2.87

Overvalued PS

6.22

Undervalued PS

0.88

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 211.82% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

HIMS News & Events

Events Timeline

No data

News

4.5

01-05Benzinga

SPDR S&P 500 ETF Trust (SPY) Year-End Price Hits $681.92

5.0

01-03Benzinga

Nike Stock Rises Nearly 3% as Insider Buying Boosts Investor Confidence

2.0

01-01Yahoo Finance

HIMS Shares Down 1.17% Amid Mixed Options Sentiment

People Also Watch

Frequently Asked Questions

What is Hims & Hers Health Inc (HIMS) stock price today?

The current price of HIMS is 31.69 USD — it has decreased -6.44 % in the last trading day.

What is Hims & Hers Health Inc (HIMS)'s business?

Hims & Hers Health, Inc. provides a consumer-first platform, which helps customers to fulfill their health and wellness needs. Its platform includes access to a provider network, a clinically focused electronic medical record system, digital prescriptions, cloud pharmacy fulfillment, and personalization capabilities. Its digital platform enables access to treatments for a range of chronic conditions, including those related to sexual health, hair loss, dermatology, mental health, and weight loss. It connects patients to licensed healthcare professionals who can prescribe medications when appropriate and prescriptions are fulfilled online through licensed pharmacies on a subscription basis. It also offers access to a range of health and wellness products designed to meet individual needs, which can include curated prescription and non-prescription products. Through its mobile applications, consumers can access a range of educational programs, wellness content, and other services.

What is the price predicton of HIMS Stock?

What is Hims & Hers Health Inc (HIMS)'s revenue for the last quarter?

Hims & Hers Health Inc revenue for the last quarter amounts to 598.98M USD, increased 49.16 % YoY.

What is Hims & Hers Health Inc (HIMS)'s earnings per share (EPS) for the last quarter?

Hims & Hers Health Inc. EPS for the last quarter amounts to 0.06 USD, decreased -81.25 % YoY.

What changes have occurred in the market's expectations for Hims & Hers Health Inc (HIMS)'s fundamentals?

How many employees does Hims & Hers Health Inc (HIMS). have?

Hims & Hers Health Inc (HIMS) has 1637 emplpoyees as of January 10 2026.

What is Hims & Hers Health Inc (HIMS) market cap?

Today HIMS has the market capitalization of 7.21B USD.